Organon & Co. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Organon & Co. (OGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 7.41% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-07-31
- Organon & Co. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 7.41%, a 23.50% increase year-over-year.
- Organon & Co. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 6.00%, a 24.48% increase year-over-year.
- Organon & Co. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 4.82%, a 54.49% increase year-over-year.
- Organon & Co. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2022-03-31 was 3.12%.
- Organon & Co. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 7.41%, a 23.50% increase from fiscal 2024.
- Organon & Co. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 6.00%, a 24.48% increase from fiscal 2023.
- Organon & Co. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 4.82%, a 54.49% increase from fiscal 2022.
- Organon & Co. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 3.12%, a 3.11% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 7.41% 10-K · filed 2026-02-24 | |||
| 2025-09-30 | 7.41% 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | 7.41% 10-Q · filed 2026-07-31 | |||
| 2025-03-31 | 7.41% 10-Q · filed 2026-05-04 | |||
| 2024-12-31 | 6.00% 10-K · filed 2026-02-24 | |||
| 2024-09-30 | 6.00% 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | 6.00% 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 6.00% 10-Q · filed 2025-05-02 | |||
| 2023-12-31 | 4.82% 10-K · filed 2026-02-24 | |||
| 2023-09-30 | 4.82% 10-Q · filed 2024-11-01 | |||
| 2023-06-30 | 4.82% 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | 4.82% 10-Q · filed 2024-05-03 | |||
| 2022-12-31 | 3.12% 10-K/A · filed 2025-11-10 | |||
| 2022-09-30 | 3.12% 10-Q · filed 2023-11-03 | |||
| 2022-06-30 | 3.12% 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | 3.12% 10-Q · filed 2023-05-05 | |||
| 2021-12-31 | 3.22% 10-K · filed 2024-02-26 | |||
| 2021-09-30 | 3.22% 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |